Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Ovarian Neoplasms

Free Subscription 27.01.2020 11 Cancer 1 Cancer Chemother Pharmacol 1 Cancer Res 5 Gynecol Oncol 1 Int J Gynaecol Obstet 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Cancer

1. VERGOTE I, Harter P, Chiva L
   Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer.
   Cancer. 2019;125 Suppl 24:4594-4597.
   PubMed     Text format     Abstract available
   
   
2. HARTER P, Heitz F, Ataseven B, Schneider S, et al
   How to manage lymph nodes in ovarian cancer.
   Cancer. 2019;125 Suppl 24:4573-4577.
   PubMed     Text format     Abstract available
   
   
3. GONZALEZ-MARTIN A, Sanchez-Lorenzo L
   Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising?
   Cancer. 2019;125 Suppl 24:4616-4622.
   PubMed     Text format     Abstract available
   
   
4. FRIEDLANDER ML
   Do all patients with recurrent ovarian cancer need systemic therapy?
   Cancer. 2019;125 Suppl 24:4602-4608.
   PubMed     Text format     Abstract available
   
   
5. KOOLE SN, van Driel WJ, Sonke GS
   Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on.
   Cancer. 2019;125 Suppl 24:4587-4593.
   PubMed     Text format     Abstract available
   
   
6. FUJIWARA K, Hasegawa K, Nagao S
   Landscape of systemic therapy for ovarian cancer in 2019: Primary therapy.
   Cancer. 2019;125 Suppl 24:4582-4586.
   PubMed     Text format     Abstract available
   
   
7. PIGNATA S, Pisano C, Di Napoli M, Cecere SC, et al
   Treatment of recurrent epithelial ovarian cancer.
   Cancer. 2019;125 Suppl 24:4609-4615.
   PubMed     Text format     Abstract available
   
   
8. SEHOULI J, Grabowski JP
   Surgery in recurrent ovarian cancer.
   Cancer. 2019;125 Suppl 24:4598-4601.
   PubMed     Text format     Abstract available
   
   
9. LEE JM, Minasian L, Kohn EC
   New strategies in ovarian cancer treatment.
   Cancer. 2019;125 Suppl 24:4623-4629.
   PubMed     Text format     Abstract available
   
   
10. AREND R, Martinez A, Szul T, Birrer MJ, et al
    Biomarkers in ovarian cancer: To be or not to be.
    Cancer. 2019;125 Suppl 24:4563-4572.
    PubMed     Text format     Abstract available
    
    
11. BOOKMAN MA
    Can we predict who lives long with ovarian cancer?
    Cancer. 2019;125 Suppl 24:4578-4581.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Chemother Pharmacol

12. MOORE K, Chan JK, Secord AA, Patel MR, et al
    Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Cancer Chemother Pharmacol. 2019;83:717-726.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

13. ZELEZNIK OA, Eliassen AH, Kraft P, Poole EM, et al
    A prospective analysis of circulating plasma metabolites associated with ovarian cancer risk.
    Cancer Res. 2020 Jan 22. pii: 0008-5472.CAN-19-2567.
    PubMed     Text format     Abstract available
    
    

    
    Gynecol Oncol

14. GHIRARDI V, Moruzzi MC, Bizzarri N, Vargiu V, et al
    Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Gynecol Oncol. 2020 Jan 14. pii: S0090-8258(20)30017.
    PubMed     Text format     Abstract available
    
    
15. MATSUO K, Machida H, Grubbs BH, Matsuzaki S, et al
    Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.
    Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31482.
    PubMed     Text format     Abstract available
    
    
16. ACOSTA-TORRES S, Fader AN
    Laparoscopic splenectomy for secondary cytoreduction of ovarian cancer in a woman with localized splenic recurrence.
    Gynecol Oncol. 2020 Jan 16. pii: S0090-8258(19)31842.
    PubMed     Text format     Abstract available
    
    
17. CADOO KA, Grisham RN, O'Cearbhaill RE, Boucicaut NN, et al
    A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
    Gynecol Oncol. 2020 Jan 17. pii: S0090-8258(20)30060.
    PubMed     Text format     Abstract available
    
    
18. SLOMOVITZ B, Gourley C, Carey MS, Malpica A, et al
    Low-grade serous ovarian cancer: State of the science.
    Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(19)31862.
    PubMed     Text format     Abstract available
    
    

    
    Int J Gynaecol Obstet

19. DAKHLY DMR, Gaafar HM, Sediek MM, Ibrahim MF, et al
    Diagnostic value of the International Ovarian Tumor Analysis (IOTA) simple rules versus pattern recognition to differentiate between malignant and benign ovarian masses.
    Int J Gynaecol Obstet. 2019 Sep 13. doi: 10.1002/ijgo.12970.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

20. CHE L, Yang X, Ge C, El-Amouri SS, et al
    Loss of BRUCE reduces cellular energy level and induces autophagy by driving activation of the AMPK-ULK1 autophagic initiating axis.
    PLoS One. 2019;14:e0216553.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: